Chemistry:Mozenavir
From HandWiki
Mozenavir (DMP-450) is an antiviral drug which was developed as a treatment for HIV/AIDS. It acts as an HIV protease inhibitor and binds to this target with high affinity,[1][2] however despite promising results in early testing,[3][4] mozenavir was unsuccessful in human clinical trials. Studies continue into related derivatives.[5]
References
- ↑ "Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors". Journal of Medicinal Chemistry 39 (11): 2156–69. May 1996. doi:10.1021/jm960083n. PMID 8667359.
- ↑ "The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues". Bioorganic & Medicinal Chemistry Letters 8 (7): 823–8. April 1998. doi:10.1016/s0960-894x(98)00119-x. PMID 9871548.
- ↑ "Highlights in the development of new antiviral agents". Mini Reviews in Medicinal Chemistry 2 (2): 163–75. April 2002. doi:10.2174/1389557024605474. PMID 12370077.
- ↑ "A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors". Journal of Medicinal Chemistry 47 (27): 6673–80. December 2004. doi:10.1021/jm0497343. PMID 15615516.
- ↑ "2-Symmetric HIV-1 Protease Inhibitors and Docking Study". Biological & Pharmaceutical Bulletin 42 (2): 261–267. 2019. doi:10.1248/bpb.b18-00705. PMID 30713256.
 |  |
